Your browser doesn't support javascript.
loading
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months.
Sobieszczyk, Magdalena E; Maaske, Jill; Falsey, Ann R; Sproule, Stephanie; Robb, Merlin L; Frenck, Robert W; Tieu, Hong-Van; Mayer, Kenneth H; Corey, Lawrence; Neuzil, Kathleen M; Tong, Tina; Brewinski Isaacs, Margaret; Janes, Holly; Bansal, Himanshu; Edwards, Lindsay M; Green, Justin A; Kelly, Elizabeth J; Shoemaker, Kathryn; Takas, Therese; White, Tom; Bhuyan, Prakash; Villafana, Tonya; Hirsch, And Ian.
Afiliação
  • Sobieszczyk ME; Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian/Columbia University Irving Medical Center, New York, New York, USA.
  • Maaske J; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Falsey AR; University of Rochester School of Medicine and Dentistry, Rochester Regional Health, Rochester, New York, USA.
  • Sproule S; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Robb ML; Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Frenck RW; Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Tieu HV; Division of Infectious Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, New York-Presbyterian/Columbia University Irving Medical Center, New York, New York, USA.
  • Mayer KH; Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA.
  • Corey L; Fenway Health, The Fenway Institute and Harvard Medical School, Boston, Massachusetts, USA.
  • Neuzil KM; University of Washington, Seattle, Washington, USA.
  • Tong T; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Brewinski Isaacs M; University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Janes H; National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
  • Bansal H; National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
  • Edwards LM; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Green JA; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Kelly EJ; Data Sciences and AI, BioPharmaceuticals R&D and.
  • Shoemaker K; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Takas T; Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • White T; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Bhuyan P; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Villafana T; Data Sciences and AI, BioPharmaceuticals R&D and.
  • Hirsch AI; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
J Clin Invest ; 132(18)2022 09 15.
Article em En | MEDLINE | ID: mdl-36106642
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article